Orforglipron

The weaker-than-hoped weight loss seen with Novo Nordisk’s CagriSema knocked the company’s shares badly on Friday. The Danish group spearheaded the GLP-1 revolution, but is now in danger of being eclipsed by newer products — or even worse, by existing ones. In last week’s readout, Novo’s amylin-GLP-1 combo allowed obese patients to lose 22.7% of their weight when using the per-protocol analysis, which excludes patients who didn’t receive the test medicine as planned. In the more conservative intent-to-treat analysis, which counts those patients as non-responders and is what would end up on the drug’s label, weight loss was 20.4%. These are respectable figures, but Novo needed more. Its stated goal was weight loss of 25%, and falling short cost it dearly, its stock closing down 17% on Friday. The data leave Novo, and all companies active in the obesity space, with several questions to answer. The placebo-adjusted weight loss seen with CagriSema (using the intent-to-treat analysis) was almost the same as that with Eli Lilly’s rival first-generation product Zepbound in its pivotal trial, though it took Lilly’s drug longer to get there. And as a combination of two molecules, CagriSema is more complicated and expensive to produce than Zepbound, and potentially less profitable. It may also turn out to have a worse safety profile. Novo has stayed largely silent on this aspect so far. A head-to-head Phase 3 trial of CagriSema and Zepbound in around 800 non-diabetic obese patients is ongoing, and could yield data towards the end of 2025. If Novo’s product lags behind Zepbound here, Novo could be in for a further fall. Again, the side-effect profile will be key. The CagriSema flop raises the possibility that there might be a maximum to the weight loss that can be achieved with incretin-based drugs. A handful of second-generation products in development could be particularly helpful in answering that question. Even drugs with the same mechanism have shown broadly varying efficacy. Novo’s older GLP-1 Saxenda has been on the market for obesity for a decade, but has never been anywhere near as effective as Wegovy and its followers. Newer products in development could be more efficacious yet, despite their shared mechanisms. For example, Lilly’s triple agonist retatrutide achieved startling results — better than both Zepbound and CagriSema — at 42 weeks in its Phase 2 trial. Roche’s CT-388, a GLP-1/GIP agonist it acquired via its $2.7 billion acquisition of Carmot, achieved steeper weight loss still, at around 19% on a placebo-adjusted basis at the six-month mark. However, these data came from a small Phase 1b trial and will need to be backed up by larger, later studies. There’s also anticipation for Viking Therapeutics’ GLP-1/GIP agonist VK2735, which allowed obese patients to lose nearly 15% after just three months’ treatment. That’s roughly on par with what Novo’s first-gen product Wegovy achieved at around a year and four months. Weight loss tends to plateau with these products at around 60 months, with patients seeing minimal effect after that point. It is possible that any of these three experimental injected products might show a step-change in the weight loss that can be achieved after many months’ treatment, breaking through the ceiling seen so far. The vast increases in manufacturing capacity Novo and Lilly have been making mean injected incretins are finally starting to reach all the new patients who need them. But what happens once patients have been taking the shots for months or years? The next battleground will be maintenance therapy, and that means oral options. Oral drugs require higher doses than subcutaneous formulations to achieve the same effect, and new manufacturing, so production capacity will be an issue all over again when the market shifts to pills. But before that, these assets will have to prove themselves in the clinic. An oral version of Novo’s Wegovy showed itself to be roughly as good as injected Wegovy when its Phase 3 trial reported last spring. However, there has been little movement on the regulatory front — Novo has not publicly said whether it has submitted the product for approval. Lilly is not trialing an oral version of Zepbound and is instead backing a different GLP-1/GIP agonist, orforglipron. That pill showed weight loss of nearly 15% after 36 weeks in a Phase 2 trial, a steeper trajectory than Novo’s pill. Phase 3 trials are ongoing. Some other big names are trying to jump straight into the oral market, though not all with success. In December 2023, Pfizer shelved the twice-weekly version of its oral GLP-1 agonist danuglipron, and is working to optimize the dose of a daily version for Phase 3. Data could come soon in 2025 , and a decision on Phase 3 will be made then. Roche has its own effort, as well. Its CT-996, also a Carmot product, managed weight loss of 7.3% after only one month, at the time the best of any pill at such an early point. This was pipped in November by Viking’s oral from of VK2735, which, dosed at 100mg, allowed weight loss of 8.2% at 28 days. However, these data come from very small Phase I trials, so they aren’t the most robust. Editor’s note: This article was corrected to include data on Viking’s oral from of VK2735. A previous version said Roche’s CT-996 was the most effective pill at one month.

MSD already has a GLP-1RA/glucagon receptor co-agonist for the treatment of MASH. Image credit: Shutterstock / Tada Images. Merck & Co (MSD) has entered an exclusive global licence agreement with China-based Hansoh Pharma for a preclinical oral small molecule glucagon-like peptide 1 receptor agonist (GLP-1RA) as it eyes the lucrative weight loss market. MSD will pay Hansoh an upfront payment of $112m to develop, manufacture and commercialise the candidate named HS-10535. Hansoh is also in line for up to $1.9bn in milestone payments, as well as royalties on sales. MSD will take on global duties of the drug while Hansoh may solely commercialise or co-promote the asset in China, as per an 18 December press release. Hansoh’s asset is orally administered, with the Chinese biopharma one of many companies developing weight loss treatment in the form of pills to provide easier options for patients compared to subcutaneous injections. Both Novo Nordisk ’s Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide) are administered via injectable pens. MSD’s move into the obesity arena is admittedly late in the day, with Eli Lilly’s oral GLP-1RA candidate orforglipron already producing positive Phase II results . Pfizer is also developing a weight loss pill – danuglipron, which met its primary endpoint in a Phase IIb trial late last year. Even though the candidate is currently at the preclinical stage, MSD is now at least in the race. The drugmaker joins an obesity market growing at an annual growth rate of 31.3%. Across the seven major markets, it is forecast to reach $37.1bn by 2031, according to GlobalData’s Pharma Intelligence Center. GlobalData is the parent company of Pharmaceutical Technology . MSD is also betting on Hansoh’s candidate working in more indications than just obesity. The drugmaker already has a GLP-1RA/glucagon receptor co-agonist, efinopegdutide, in Phase II trials for metabolic dysfunction-associated steatohepatitis (MASH), but HS-10535 could provide wider coverage across more indications. In a statement following the deal for HS-10535, MSD’s research laboratories president Dr Dean Y Li said the therapy has the “potential to provide additional cardiometabolic benefits beyond weight reduction”. The deal with Hansoh is the latest in a long line of money moves by MSD this year as it looks to enhance its portfolio amid blockbuster drug Keytruda’s (pembrolizumab) impending patent loss. Deals this year for MSD include a $1.9bn deal with fibroblast therapy company Mestag Therapeutics and a $1.3bn acquisition of EyeBio . MSD is not the only company to tap China’s biopharma scene for a preclinical obesity asset – AstraZeneca followed the same path in November 2023 in a deal worth up to $2.01bn with Eccogene.